A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

J. E. Grilley-Olson, University of North Florida
P. L. Bedard, Ontario Cancer Institute University of Toronto
A. Fasolo, IRCCS San Raffaele Scientific Institute
M. Cornfeld, GlaxoSmithKline, USA
L. Cartee, GlaxoSmithKline, USA
A. R.Abdul Razak, Ontario Cancer Institute University of Toronto
L. A. Stayner, Ontario Cancer Institute University of Toronto
Y. Wu, GlaxoSmithKline, USA
R. Greenwood, GlaxoSmithKline, USA
R. Singh, GlaxoSmithKline, USA
C. B. Lee, University of North Florida
J. Bendell, Sarah Cannon Research Institute
H. A. Burris, Sarah Cannon Research Institute
G. Del Conte, IRCCS San Raffaele Scientific Institute
C. Sessa, IRCCS San Raffaele Scientific Institute
J. R. Infante, Sarah Cannon Research Institute


Introduction This Phase Ib trial investigated the safety, tolerability, and recommended phase 2 dose for the pan-PI3K/mTOR inhibitor, GSK2126458 (GSK458), and trametinib combination when administered to patients with advanced solid tumors. Patients and Methods Patients with advanced solid tumors received escalating doses of GSK458 (once or twice daily, and continuous or intermittent) and trametinib following a zone-based 3 + 3 design to determine the maximum tolerated dose (MTD). Assessments included monitoring for adverse events and response, and evaluating pharmacokinetic (PK) measures. Archival tissue and circulating free DNA samples were collected to assess biomarkers of response in the PI3K and RAS pathways. Results 57 patients were enrolled onto the continuous dosing cohort and 12 patients onto an intermittent BID dosing cohort. Two MTDs were established for the continuous daily dosing: 2 mg of GSK458 with 1.0 mg of trametinib or 1.0 mg of GSK458 with 1.5 mg of trametinib; no MTD was determined in the intermittent dosing cohort. The most frequent adverse events were rash (74 %) and diarrhea (61 %). Dose interruptions due to adverse events occurred in 42 % of patients. No significant PK interaction was observed. One patient achieved partial response and 12 patients had stable disease >16 weeks. Mutations in RAS/RAF/PI3K were detected in 70 % of patients, but no pattern emerged between response and mutational status. Conclusion GSK458 plus trametinib is poorly tolerated, due to skin and GI-related toxicities. Responses were minimal, despite enrichment for PI3K/RAS pathway driven tumors, which may be due to overlapping toxicities precluding sufficient dose exposure.